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I n t r o d u c t i o n  
The aim of this chapter is to address the possible opportunities for knowledge valoriza-
tion based on the described research findings in this thesis. Knowledge valorization, 
knowledge transfer or commercialization are similar terms that all refer to the “process 
of creating value from knowledge, by making knowledge suitable and/or available for 
social and economic use and by making knowledge suitable for translation into competi-
tive products, services, processes and new commercial activities”.
1,2
  
R e l e v a n c e  
Acute myocardial infarction (AMI) and (unstable) angina, components of the clinical 
definition ‘(acute) coronary syndrome’, are major causes of death and disability world-
wide.
3
 In 2011, 9,876 individuals in the Netherlands died of coronary disease, with the 
majority of deaths (n = 6,467, 65%) resulting from AMI.
4
 In the same year, 115,921 
subjects with coronary disease were admitted to a hospital in the Netherlands, which 
accounted for 3% of all hospital admissions in the Netherlands in 2011.
4
 This resulted in 
an economic healthcare burden of €2.1 billion, which corresponded to 2.3% of the total 
amount of healthcare costs in 2011 in the Netherlands.
5
 
 Patients with acute chest pain or other symptoms suggestive of AMI account for 
more than 10% of all emergency department consultations.
6
 As the majority of these 
patients will be found not to have AMI, the diagnosis (rule-in) and rule-out of AMI 
seems to be equally important.
7
 In addition, rapid and accurate diagnosis of AMI is of 
paramount clinical importance: delayed ‘rule-in’ of AMI increases morbidity and mortal-
ity, whereas delayed ‘rule-out’ causes anxiety in patients and excessive health care 
costs due to prolonged time spent at the emergency department.
8
 Most patients with 
AMI have a non-diagnostic ECG and require serial blood sampling and measurement of 
cardiac troponins (cTn) as part of the clinical workup.
3
 The clinical presentation of the 
patient, in conjunction with a typical ‘rise or fall’ of cTn concentrations between serial 
measurements, establishes the diagnosis.
3
 In 2013, cTn were measured in 3,585 blood 
samples collected from patients presenting at the cardiac emergency department of 
Maastricht University Medical Center.  
 The analytical performance of the troponin assays has improved enormously over 
the last 5 years. Patients diagnosed with the ‘high-sensitivity’ (hs) troponin assays 
demonstrate a clear survival benefit compared to patients diagnosed with conventional 
troponin assays, due to an improved diagnostic sensitivity.
9
 However, the diagnosis of 
AMI with the hs assays is more complex, which arises from the detection of previously 
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unnoticed cTn elevations in patients with cardiomyocyte injury other than AMI.
10
 This 
includes acute heart failure, type 2 diabetes, and even cTn elevations in healthy recrea-
tional athletes after an acute bout of endurance-type exercise. This lack in specificity is 
a challenge for clinicians. Therefore, it is essential to increase our understanding on how 
to interpret levels of cTn in settings of serial testing and endurance-type exercise.  
 On the contrary, the improvement in analytical sensitivity has resulted in more 
applications of cTn. Even when adjusted for traditional cardiovascular risk factors (such 
as smoking, diabetes, hyperlipidemia and hypertension), cTn concentrations below the 
clinical cut-off value for AMI measured in the general population are strongly associated 
with an increased risk of developing cardiovascular events and all-cause or cardiovascu-
lar mortality.
11
 As traditional risk factors do not identify everyone who will eventually 
develop cardiovascular disease,
12
 cTn are promising candidates to refine risk stratifica-
tion models for the primary prevention of cardiovascular disease.  
T a r g e t  g r o u p s  
Interpretation of troponin levels are mainly performed by clinicians (e.g. cardiologists, 
general practitioners) and laboratory specialists. In addition, the results described in this 
thesis could be of interest to diagnostic companies (e.g. Roche Diagnostics, Abbott 
Diagnostics, Beckman Coulter) that are involved with the development, optimization, 
implementation or application of a specific troponin assay. Research described in this 
thesis also has the potential to be of interest for (recreational) athletes.  
A c t i v i t i e s  
The results described in this thesis can be translated into several activities or tools. 
These activities are clustered according to the three mechanisms of knowledge transfer; 
through results or commercialization, people and via cooperation (figure 1).  
 This thesis describes the presence of a diurnal rhythm of cTn. As this physiological 
fall-and-rise during day and night may provide an explanation in isolated cases of pa-
tients where the clinical assessment is discordant with biochemical results, awareness 
of the presence of a physiological rhythm is important among individuals that interpret 
concentrations of cTn. This can be achieved via interaction with clinicians and laborato-
ry specialists (e.g. presentations, dialogues, conferences) or via lectures for medicine 
students of Maastricht University Medical Center. This level of knowledge utilization has 
already been started through publication of results in the Journal of the American Col-
lege of Cardiology, a high impact cardiology journal, and through oral presentations at 
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national and international conferences (IFCC, Istanbul, 2014). Additional novel insights 
arising from future studies will further enhance awareness through publications and 
presentations. The second step of knowledge utilization is to connect with key-opinion 
leaders that comprise the writing group on behalf of the joint ESC / ACCF / AHA / WHF 
Task Force for the Universal Definition of Myocardial Infarction.
3
 This level of knowledge 
transfer has been initiated by the collaboration with the research group of Prof. dr. 
Mueller (University Hospital Basel, Switzerland), a senior scientist behind major break-
throughs related to the optimal diagnostic algorithm of cTn for the diagnosis of AMI. 
The final step is the actual integration of the diurnal rhythm into guidelines such as the 
expert consensus document ‘Universal definition of myocardial infarction’.
3
 
 
 
Figure 1. Potential knowledge transfer activities based on the research 
findings described in this thesis. 
 
 Results of this thesis support the concept that cTn can be implemented into risk-
stratification scores to identify individuals in the general population at risk for cardio-
vascular diseases. The national guideline for general practitioners recommends to de-
termine the risk and need for prevention consultation for patients according to a medi-
cal risk questionnaire, without the measurement of biomarkers.
13
 To initiate the first 
step of knowledge utilization (awareness), future studies should aim to determine the 
additional value of cTn concentrations in this risk calculation tool used by general practi-
tioners.  
 The research findings concerning exercise-induced cTn release have the potential 
to be utilized by (recreational) athletes. The first step would be to organize information 
meetings and discuss the effects of endurance-type exercise. To initiate this first step of 
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valorization, more studies are needed to make a definite statement regarding the un-
derlying process (i.e. physiological or pathological) of exercise-induced cTn release.  
 Troponin testing involves the measurement of one of two proteins – cardiac tro-
ponin T (cTnT) or I (cTnI) – with distinct biochemical properties, but comparable diag-
nostic performance.
14
 A recent European survey demonstrated that 50% of the inquired 
laboratories use cTnT and 45% use cTnI concentrations as part of the diagnostic workup 
for AMI.
15
 This thesis described minor differences between cTnT and cTnI in terms of 
their diurnal variation and prognostic value. Future studies should aim to compare cTnT 
and cTnI measured by hs assays across the broad spectrum of cardiovascular disease. 
Awareness of these comparisons among the individuals that interpret cTn concentra-
tions have the potential to result in a pathophysiological preference of one troponin 
biomarker over another and could influence the troponin test offered by the clinical 
laboratory.  
 cTn are already incorporated into clinical practice. Therefore, research focusing on 
the biomarker has the potential for cooperation with diagnostic companies regarding 
for example the implementation and evaluation of troponin assays. The first level in this 
knowledge transfer activity has already been initiated, as the Central Diagnostic Labora-
tory of Maastricht has excellent collaborations with Roche Diagnostics, Abbott Diagnos-
tics and Beckman Coulter.  
C o n c l u s i o n  
Research findings of this thesis can be translated into several knowledge transfer activi-
ties involving people, results and cooperation. Although the outcomes of these mecha-
nisms of knowledge utilization are different, the first step, i.e. creating awareness 
through publications or presentations, is identical among all knowledge utilization activ-
ities.   
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